Antibody-drug conjugates (ADC) represent a new way to treat cancer. ADC are comprised of an antibody, a linker, and a payload. Unlike traditional chemotherapy, ADC are targeted to impair cancer cells, while sparing healthy cells. In this course, we discuss how ADC were developed, and their mechanism of action. We also review several different ADC therapies and the differences between them. Come discover why ADC are of the fastest growing cancer therapies and how they will affect our patients.
Speaker: Dr. Hossein Borghaei
To earn 1 hour of free COPE approved enduring CE in the pharmacology category, please visit our site and take the post test: [ Ссылка ]
